

Remark:

The first paragraph under the heading "BACKGROUND OF THE INVENTION" is amended to reflect the updated status of the parent patent applications. U.S. patent applications 09/685311 had been matured into issued U.S. patent 6,629,014. U.S. patent application 10/193,838 filed as national phase of the parent PCT/US01/01923 is now pending issue. Per the discussion in the telephone conference on April 14, 2005, the examiner is alert to the existence of the closely related parent application 10/193,838 pending issue.

The office action dated 6/16/2005 requires the applicant to further elect species of the claims. Accordingly the applicant elects the generic claim 40, claim 1 depending on claim 40, and claims 2, 48 to 51, which further depend on claim 1. Please note that claim 40 is generic to other pending claims. In fact, the group claim 40, 1 and 2 specified by the examiner is not characterized by a species defining n available garment sizes. This is because any BP Code system as claimed, in general also defines n garment sizes. The characteristic of the group Claim 40, 1 and 2 is characterized by the relationship between BP Code and it's application with a size chart. Since the restriction requirement results in an inadequate clarification of this elected species, claims 48 to 51 are added to further specify the claimed scope of this elected group. Claim 48 to 50 adds further limitations to the dependent claim 1 by describing a key characteristic how the BP Code is formed to work with a garment size chart. Claim 51 indicates how the elected species helps a second person to purchase a best-fitted garment for a first person. Accordingly the group elected above satisfies the requirements of the patent laws for proceeding into the examination process.

Finally, this is to document a request for the examiner to reconsider the allowance of the non-elected claims 42 to 47 if the generic claim 40 is allowable in the future. This is because claims 42 to 47 recites the essences of the key current claims dependent on the generic claim 40.